EA020398B1 - Антитела к с-мет - Google Patents

Антитела к с-мет Download PDF

Info

Publication number
EA020398B1
EA020398B1 EA201170716A EA201170716A EA020398B1 EA 020398 B1 EA020398 B1 EA 020398B1 EA 201170716 A EA201170716 A EA 201170716A EA 201170716 A EA201170716 A EA 201170716A EA 020398 B1 EA020398 B1 EA 020398B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
acid sequence
antibodies
antibody
binding fragment
Prior art date
Application number
EA201170716A
Other languages
English (en)
Russian (ru)
Other versions
EA201170716A1 (ru
Inventor
Джулиан Дэвис
Лин Лю
Цзижун Лу
Питер Эдвард Вайлланкур
Марк Эндрю Уортинджер
Вэй Цзэн
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201170716A1 publication Critical patent/EA201170716A1/ru
Publication of EA020398B1 publication Critical patent/EA020398B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201170716A 2008-11-21 2009-11-18 Антитела к с-мет EA020398B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11682508P 2008-11-21 2008-11-21
US21990309P 2009-06-24 2009-06-24
PCT/US2009/064881 WO2010059654A1 (en) 2008-11-21 2009-11-18 c-MET ANTIBODIES

Publications (2)

Publication Number Publication Date
EA201170716A1 EA201170716A1 (ru) 2011-12-30
EA020398B1 true EA020398B1 (ru) 2014-10-30

Family

ID=41435259

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170716A EA020398B1 (ru) 2008-11-21 2009-11-18 Антитела к с-мет

Country Status (27)

Country Link
US (2) US8217148B2 (https=)
EP (2) EP2358755B1 (https=)
JP (1) JP5688027B2 (https=)
KR (1) KR101334450B1 (https=)
CN (1) CN102216333B (https=)
AR (1) AR074360A1 (https=)
AU (1) AU2009316742B2 (https=)
BR (1) BRPI0922800A2 (https=)
CA (1) CA2743508C (https=)
CY (1) CY1116886T1 (https=)
DK (1) DK2358755T3 (https=)
EA (1) EA020398B1 (https=)
ES (2) ES2663825T3 (https=)
HR (1) HRP20151019T1 (https=)
HU (1) HUE026058T2 (https=)
IL (1) IL212633A (https=)
JO (1) JO3097B1 (https=)
MX (1) MX2011005400A (https=)
NZ (1) NZ592215A (https=)
PA (1) PA8849001A1 (https=)
PL (1) PL2358755T3 (https=)
PT (1) PT2358755E (https=)
SI (1) SI2358755T1 (https=)
TR (1) TR201802841T4 (https=)
TW (1) TWI477284B (https=)
WO (1) WO2010059654A1 (https=)
ZA (1) ZA201103586B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2751720C2 (ru) * 2017-05-30 2021-07-16 Чонг Кун Данг Фармасьютикал Корп. Новое анти-с-мет антитело и его применение
US12528870B2 (en) 2020-09-01 2026-01-20 Remegen Co., Ltd. Anti-c-Met antibody-drug conjugate and applications thereof

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
EP2576622A4 (en) * 2010-06-01 2013-11-27 Univ Monash ON THE UNPROCESSED RECEPTOR TYROSINE KINASE C-MET TARGETED ANTIBODIES
MX2013002084A (es) 2010-08-31 2013-05-09 Genentech Inc Biomarcadores y metodos de tratamiento.
KR20140019284A (ko) * 2010-09-03 2014-02-14 아카데미아 시니카 항-C-Met 항체 및 이의 이용 방법들
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
CN102276726B (zh) * 2011-03-16 2014-02-19 常州新泉生物医药科技有限公司 肝细胞生长因子受体活性基团的融合蛋白
US20140301989A1 (en) * 2011-06-17 2014-10-09 Brian Johnstone Methods for increasing the potency and efficacy of stem cells
SG11201400724SA (en) 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2785741A1 (en) 2011-12-02 2014-10-08 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
WO2013169532A1 (en) * 2012-05-09 2013-11-14 Eli Lilly And Company Anti-c-met antibodies
CN105050618B (zh) * 2012-06-21 2018-11-16 索伦托治疗有限公司 与c-Met结合的抗原结合蛋白
EP2708556B1 (en) * 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
CN105452297B (zh) * 2013-04-30 2019-10-11 新加坡科技研究局 mAb 2抗-Met抗体
CN105745335A (zh) * 2013-08-14 2016-07-06 佳根曼斯菲尔德有限公司 用于对cMET核酸进行多模态分析的组合物及方法
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2748295T3 (es) * 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
WO2017019454A2 (en) * 2015-07-28 2017-02-02 Musc Foundation For Research Development Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase
CN108350078A (zh) 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
KR102476846B1 (ko) * 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―ｃ―ＭＥＴ 항체 및 이의 용도
GB2551372A (en) * 2016-06-16 2017-12-20 Bombardier Primove Gmbh A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer
MA45412A (fr) 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
CN107556387A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
WO2018021188A1 (ja) * 2016-07-26 2018-02-01 学校法人日本大学 歯周炎治療薬及び歯周炎治療用組成物
US10439449B2 (en) 2016-08-10 2019-10-08 Microsoft Technology Licensing, Llc Coupling device modules for inductive data transmission
MX420249B (es) * 2016-09-29 2025-02-10 Mitsubishi Tanabe Pharma Corp Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos.
JP7066696B2 (ja) * 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP6709340B2 (ja) 2016-11-16 2020-06-10 イーライ リリー アンド カンパニー エクソン１４スキッピング変異（複数可）またはエクソン１４スキッピング表現型を有するがんの併用療法
HRP20210922T1 (hr) * 2016-11-23 2021-09-03 Eli Lilly And Company Konjugati protutijela protiv met s lijekom
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN106986932A (zh) * 2017-04-06 2017-07-28 海口市人民医院 一种c‑Met表位肽及其应用
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
RS66266B1 (sr) * 2021-02-03 2024-12-31 Mythic Therapeutics Inc Anti-met antitela i njihova primena
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
BR112023020801A2 (pt) 2021-04-08 2023-12-12 Byondis Bv Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CN113788895B (zh) * 2021-10-14 2023-09-15 陕西健吉跃生物科技有限公司 一种兔多克隆抗体及其制备方法和应用
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
EP4713360A1 (en) 2023-05-19 2026-03-25 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038557A1 (en) * 1995-06-02 1996-12-05 Genentech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2007126799A2 (en) * 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2102595C (en) * 1991-05-10 2003-01-14 Paolo Comoglio Truncated forms of the hepatocyte growth factor (hgf) receptor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
ITMI20031127A1 (it) * 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
NZ561211A (en) 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
ES2368864T3 (es) 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
JP2009529000A (ja) * 2006-02-22 2009-08-13 イーライ リリー アンド カンパニー ヒト化抗グレリン抗体
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR20090113325A (ko) * 2007-02-08 2009-10-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 흑색종에서의 ｇｎａｑ 돌연변이
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038557A1 (en) * 1995-06-02 1996-12-05 Genentech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
WO2005016382A1 (en) * 2003-08-04 2005-02-24 Pfizer Products Inc. Antibodies to c-met
WO2007126799A2 (en) * 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAUD NEIL R. ET AL.: "Targeting the hepatocyte growth factor receptor c-Met with neutralizing human monoclonal antibodies for the treatment of cancer (abstract 3027)" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 47, April 2006 (2006-04), pages 712-713, XP002562170 & 97TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); WASHINGTON, DC, USA; APRIL 01-05, 2006 ISSN: 0197-016X abstract *
TSENG JEFFREY R. ET AL.: "Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET." JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE JAN 2008, vol. 49, no. 1, January 2008 (2008-01), pages 129-134, XP002562169 ISSN: 0161-5505 page 129, right-hand column, last paragraph page 130, right-hand column, last paragraph page 131, right-hand column, last paragraph *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2751720C2 (ru) * 2017-05-30 2021-07-16 Чонг Кун Данг Фармасьютикал Корп. Новое анти-с-мет антитело и его применение
US11479612B2 (en) 2017-05-30 2022-10-25 Chong Kun Dang Pharmaceutical Corp. Anti-c-Met antibody and use thereof
US12528870B2 (en) 2020-09-01 2026-01-20 Remegen Co., Ltd. Anti-c-Met antibody-drug conjugate and applications thereof

Also Published As

Publication number Publication date
CY1116886T1 (el) 2017-04-05
DK2358755T3 (en) 2015-11-16
KR20110074612A (ko) 2011-06-30
AU2009316742B2 (en) 2012-06-07
NZ592215A (en) 2012-09-28
TWI477284B (zh) 2015-03-21
KR101334450B1 (ko) 2013-12-02
ES2663825T3 (es) 2018-04-17
BRPI0922800A2 (pt) 2015-12-22
MX2011005400A (es) 2011-06-20
CN102216333A (zh) 2011-10-12
PA8849001A1 (es) 2010-06-28
US8398974B2 (en) 2013-03-19
TW201023885A (en) 2010-07-01
CA2743508C (en) 2016-07-19
ZA201103586B (en) 2013-10-30
WO2010059654A1 (en) 2010-05-27
JP5688027B2 (ja) 2015-03-25
AR074360A1 (es) 2011-01-12
EP2963058A1 (en) 2016-01-06
CN102216333B (zh) 2014-05-21
HUE026058T2 (en) 2016-05-30
SI2358755T1 (sl) 2015-10-30
HRP20151019T1 (hr) 2015-10-23
AU2009316742A1 (en) 2010-05-27
JO3097B1 (ar) 2017-03-15
US8217148B2 (en) 2012-07-10
HK1158229A1 (en) 2012-07-13
PL2358755T3 (pl) 2016-01-29
ES2549760T3 (es) 2015-11-02
PT2358755E (pt) 2015-11-12
EP2963058B1 (en) 2018-02-21
JP2012509881A (ja) 2012-04-26
EP2358755B1 (en) 2015-09-02
EP2358755A1 (en) 2011-08-24
US20100129369A1 (en) 2010-05-27
EA201170716A1 (ru) 2011-12-30
IL212633A (en) 2015-03-31
CA2743508A1 (en) 2010-05-27
IL212633A0 (en) 2011-07-31
US20120263723A1 (en) 2012-10-18
TR201802841T4 (tr) 2018-03-21

Similar Documents

Publication Publication Date Title
EA020398B1 (ru) Антитела к с-мет
Neijssen et al. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
RU2546254C9 (ru) Моноклональные антитела к рецептору 2 фактора роста фибробластов
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
ES2346886T3 (es) Anticuerpos monoclonales para el factor de crecimiento de hepatocitos.
US8101725B2 (en) Monoclonal antibodies to basic fibroblast growth factor
WO2021260583A1 (en) Combination of antibody-drug conjugate and dna-pk inhibitor
TWI743051B (zh) 抗-met抗體及其使用方式
KR20170085595A (ko) 혈뇌 장벽 수용체 항체 및 사용 방법
JP2019510739A (ja) Ｇｆｒａｌ受容体療法
EP4386009A1 (en) Bispecific fusion polypeptide and application thereof
US20220213216A1 (en) Bispecific antibody with double her2 sites for tumor immunotherapy
US20230398227A1 (en) Medicine for treating cancer
EP3082858B1 (en) Adrenomedullin binder for use in therapy of cancer
KR102952495B1 (ko) 항-cxcr2 항체 및 이의 용도
KR20180079232A (ko) L1cam 단백질에 특이적으로 결합하는 항체 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4700046A1 (en) Anti-cxcr2 antibody and use thereof
WO2011080401A1 (en) Receptor tyrosine kinase-binding compositions
US20060051352A1 (en) CEA binding agents and compositions to reverse CEA-mediated tumorigenic effects on human cancer cells, restore sensitivity to drug induced apoptosis and uses thereof
CN110291110A (zh) 特异性结合pauf蛋白的抗体及其用途
HK1240242A1 (en) Blood brain barrier receptor antibodies and methods of use

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KZ RU